Health Care

Merck’s Phase III wins for Keytruda + WELIREG and Keytruda + Padcev could boost kidney‑cancer and bladder‑cancer sales by over $1 billion, reshaping the oncology landscape.

Solventum Corp’s Q4 earnings beat highlights strong wound‑care and sterilization growth, but investors caution on margin risk and competitive pressures.

Illumina partners with Florida State University’s IPRD to bring CLIA‑certified whole‑genome sequencing, speeding diagnosis for rare pediatric genetic diseases.

Nemolizumab shows 3‑year itch relief and quality‑of‑life benefits in prurigo nodularis with a safe profile, supporting long‑term use and guideline inclusion.

Amgen’s stock rises as breakthrough CRISPR‑CAR‑T for pancreatic cancer and an ADC for CKD gain FDA designations, promising new revenue streams and investor confidence.

Smith & Nepphew plc’s March earnings reveal how the medical‑device leader balances NHS value‑based pricing, cost savings, and R&D investment to outpace industry growth.

HCA Healthcare’s March conference plans, share‑price moves, Asheville campus shift, and diagnostics/therapeutics expansion show a data‑driven strategy for growth and patient‑care excellence.

Explore UHS’s Q4 earnings, behavioral‑health surge, payment‑reform risks, and debt challenges—why a cautious, data‑driven view beats blind optimism.

Boston Scientific’s Q1 2026 results, TD Cowen strategy talks and ownership shifts signal new growth, AI‑driven device innovation, ESG focus, and supply‑chain resilience ahead of the stock’s next move.

Centene’s stock trades near its 52‑week low, yet its vast Medicaid/Medicare network offers a stable base—watch policy shifts and earnings for upside.